Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
April 06 2021 - 8:00AM
Esperion (NASDAQ: ESPR), today announced that president and chief
executive officer, Tim M. Mayleben, will participate in an
analyst-led fireside chat at the 20th Annual Needham Virtual
Healthcare Conference on Tuesday, April 13, 2021, at 9:30 a.m.
Eastern Time.
Event: |
20th Annual
Needham Virtual Healthcare Conference |
Date: |
April 13, 2021 |
Format: |
Fireside chat & 1:1 Investor meetings |
Time: |
9:30 a.m. ET |
A live audio webcast of this event can be accessed on the
investor relations section of the Esperion website at
www.esperion.com/investors-media/events-presentations/. Replay of
the webcast will be archived on the Company's website for 90 days
following the event.
Esperion Therapeutics
Through scientific and clinical excellence, and a deep
understanding of cholesterol biology, the experienced Lipid
Management Team at Esperion is committed to developing new LDL-C
lowering medicines that will make a substantial impact on reducing
global cardiovascular disease, the leading cause of death around
the world. For more information, please visit www.esperion.com and
follow us on Twitter at www.twitter.com/EsperionInc.
Esperion Therapeutics’ Commitment to Patients with
Hyperlipidemia
High levels of LDL-C can lead to a build-up of fat and
cholesterol in and on artery walls (known as atherosclerosis),
potentially leading to cardiovascular events, including heart
attack and stroke. In the U.S., 96 million people, or more than 37
percent of the adult population, have elevated LDL-C. There are
approximately 18 million people in the U.S. living with elevated
levels of LDL-C despite taking maximally tolerated lipid-modifying
therapy — including individuals considered statin averse — leaving
them at high risk for cardiovascular events1. In the United States,
more than 50 percent of atherosclerotic cardiovascular disease
(ASCVD) patients and heterozygous familial hypercholesterolemia
(HeFH) patients who are not able to reach their guideline
recommended LDL-C levels with statins alone need less than a 40
percent reduction to reach their LDL-C threshold goal2.
Esperion's mission as the Lipid Management Company is to deliver
oral, once-daily medicines that complement existing oral drugs to
provide the additional LDL-C lowering that these patients need.
References(1) Esperion market
research on file: research project interviewing 350 physicians.
Esperion Therapeutics, Inc. Sept-Oct 2018.(2) Data on
file: analysis of NHANES database. Esperion Therapeutics, Inc.
2018.
Investor Contact:Kaitlyn
BroscoEsperioncorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024